Search Results

You are looking at 11 - 20 of 69 items for :

  • "bisphosphonates" x
Clear All
Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman and Matthew R. Smith

2004 ; 350 : 1655 – 1664 . 3 Coleman RE . Bisphosphonates: clinical experience . Oncologist 2004 ; 9 ( Suppl 4 ): 14 – 27 . 4 Fidler IJ . Cancer metastasis . Br Med Bull 1991 ; 47 : 157 – 177 . 5 Mohler J Amling

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith and Catherine H. Van Poznak

in patients with a history of cancer. Bisphosphonates have been shown to reduce incidence of both vertebral and hip fracture and may be the drugs of choice for cancer survivors. Initial preventive strategies for osteoporosis consist of adequate intake

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. Vose, Donna Weber, Joachim Yahalom and Furhan Yunus

Bloomfield DJ . Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review . J Clin Oncol 1998 ; 16 : 1218 – 1225 . 102 Kyle RA Yee GC Somerfield MR

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom and Furhan Yunus

to be HLA-typed. Because bisphosphonate therapy is a consideration in patients with MM, a baseline bone densitometry test may be recommended. Diagnostic Categories Based on the results of the clinical and laboratory evaluation discussed in

Full access

Azeez Farooki

York City, who served on the NCCN Bone Health in Cancer Care Task Forces in 2008 and 2012. Bisphosphonates and denosumab have been extensively studied both for prevention of bone loss due to cancer therapies and for prevention of skeletal-related events

Full access

Noopur S. Raje, Andrew J. Yee and G. David Roodman

Bisphosphonates Bisphosphonates, such as pamidronate and zoledronate, play a fundamental role in minimizing and managing bone-related complications in MM. 14 , 15 Bisphosphonates are drugs that share a phosphorus-carbon-phosphorus backbone and accumulate in the

Full access

Charles P. Borden, Charles L. Shapiro, Maria Teresa Ramirez, Linda Kotur and William Farrar

the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer recommendation that all patients diagnosed with skeletal metastases receive bisphosphonates. The cancer program at OSUCCC uses a variety of tools for process

Full access

Philip L. McCarthy

asked whether intravenous versus oral bisphosphonates would have different effects on the incidence of skeletal-related events, so this form of therapy would not be considered maintenance therapy but more supportive care. All patients were randomized to

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas and Catherine H. Van Poznak

: Nonpharmacologic Components” (page S-8) for information on correcting vitamin D deficiency. e After 3–5 years of potent antiresorptive therapy (bisphosphonate or denosumab), or after cancer therapy posing a risk for bone loss is stopped, reassess fracture risk

Full access

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz and Ghassan K. Abou-Alfa

, bisphosphonates, and sorafenib, and the number of SREs per patient were also recorded. Statistical Analysis Descriptive statistics were used to tabulate patient demographics and determine the prevalence of bone metastasis in the cohort. In patients without